SCHEMBL4820977

SCHEMBL4820977

CC1(C)CCN(C(=O)Cc2csc(-c3cnccn3)n2)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
EGLN1 Q9GZT9 1/20 0.41
CPT2 P23786 1/20 0.40
CPT1A P50416 1/20 0.40
CPT1B Q92523 1/20 0.40
KLKB1 P03952 1/20 0.40
KLK1 P06870 1/20 0.40
RORC P51449 1/20 0.38
BCL2 P10415 1/20 0.37
CYP3A4 P08684 3/20 0.36
HIF1A Q16665 2/20 0.36
USP2 O75604 2/20 0.36
LMNA P02545 1/20 0.36
CYP2D6 P10635 2/20 0.36
CDC7 O00311 1/20 0.35
DBF4 Q9UBU7 1/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP2C9 P11712 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4820969 1.00 HDAC1 (0.43) HDAC1HDAC8HDAC6EGLN1CPT2
SCHEMBL4817388 0.83 HDAC1 (0.43) HDAC1HDAC8HDAC6EGLN1CPT2
SCHEMBL4022290 0.76 HDAC1 (0.55) HDAC1HDAC8HDAC6EGLN1CPT2
SCHEMBL5245114 0.75 HDAC1 (0.53) HDAC1HDAC8HDAC6EGLN1CPT2
SCHEMBL3451193 0.70 HDAC1 (0.52) HDAC1HDAC8HDAC6CPT2CPT1A
SCHEMBL5382825 0.67 HDAC1 (0.49) HDAC1HDAC8HDAC6CPT2CPT1A
SCHEMBL17503927 0.65 KLKB1 (0.54) HDAC1HDAC8HDAC6CPT2CPT1A
SCHEMBL1999671 0.64 HDAC1 (0.71) HDAC1HDAC8HDAC6CPT2CPT1A
SCHEMBL4820539 0.63 HPGD (0.51) CYP3A4LMNACYP2D6ALDH1A1CYP2C9
SCHEMBL4820548 0.63 HPGD (0.51) CYP3A4LMNACYP2D6ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7402606-B2 Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss SMITHKLINE BEECHAM CORPORATION (US) 2008-07-22 US claimed
EP-1494663-A1 DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS SmithKline Beecham Corporation (US) 2005-01-12 EP claimed
WO-2003086385-A1 DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS SMITHKLINE BEECHAM CORPORATION (US) 2003-10-23 WO claimed
US-7402606-B2 Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss SMITHKLINE BEECHAM CORPORATION (US) 2008-07-22 US disclosed
EP-1494663-A1 DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS SmithKline Beecham Corporation (US) 2005-01-12 EP disclosed
WO-2003086385-A1 DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS SMITHKLINE BEECHAM CORPORATION (US) 2003-10-23 WO disclosed